On-treatment lipoprotein components and risk of cerebrovascular events in the Treating to New Targets study

European Journal of Clinical Investigation

Volumn 41, Issue 2, 2011, Pages 134-142

  Van den Bogaard, Bas ^a   Van den Born, Bert Jan H ^a   Fayyad, Rana ^b   Waters, David D ^c   DeMicco, David A ^b   LaRosa, John C ^d   Kastelein, John J ^a   Holme, Ingar ^e  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b PFIZER INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Lipoproteins; Statins; Stroke; Transient ischaemic attack

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CEREBROVASCULAR DISEASE; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; STROKE; SYSTOLIC BLOOD PRESSURE; TRANSIENT ISCHEMIC ATTACK;

AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISCHEMIC ATTACK, TRANSIENT; LIPOPROTEINS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; STROKE; TIME FACTORS;

EID: 78651320028     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2010.02387.x     Document Type: Article

References (24)

1. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55, 000 vascular deaths. Lancet 2007;370:1829-39.
2. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
3. Waters DD, LaRosa JC, Barter P, Fruchart JC, Gotto AM Jr, Carter R et al. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. J Am Coll Cardiol 2006;48:1793-9.
4. LaRosa JC, Grundy SM, Kastelein JJ, Kostis JB, Greten H. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). Am J Cardiol 2007;100:747-52.
5. Kastelein JJ, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 2008;117:3002-9.
6. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.
7. Waters DD, Guyton JR, Herrington DM, McGowan MP, Wenger NK, Shear C. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol 2004;93:154-8.
8. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
9. Albers JJ, Marcovina SM, Kennedy H. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. II. Evaluation and selection of candidate reference materials. Clin Chem 1992;38:658-62.
10. Amarenco P, Bogousslavsky J, Callahan A III, Goldstein LB, Hennerici M, Rudolph AE et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-59.
11. Amarenco P, Goldstein LB, Szarek M, Sillesen H, Rudolph AE, Callahan A III et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2007;38:3198-204.
12. van der Steeg WA, Boekholdt SM, Stein EA, El-Harchaoui K, Stroes ES, Sandhu MS et al. Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Ann Intern Med 2007;146:640-8.
13. Simes RJ, Marschner IC, Hunt D, Colquhoun D, Sullivan D, Stewart RA et al. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 2002;105:1162-9.
14. Gotto AM Jr, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000;101:477-84.
15. Scharnagl H, Nauck M, Wieland H, Marz W. The Friedewald formula underestimates LDL cholesterol at low concentrations. Clin Chem Lab Med 2001;39:426-31.
16. Amarenco P, Labreuche J, Touboul PJ. High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review. Atherosclerosis 2008;196:489-96.
17. Tirschwell DL, Smith NL, Heckbert SR, Lemaitre RN, Longstreth WT Jr, Psaty BM. Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology 2004;63:1868-75.
18. Sacco RL, Benson RT, Kargman DE, Boden-Albala B, Tuck C, Lin IF et al. High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA 2001;285:2729-35.
19. Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G. Relationships between lipoprotein components and risk of ischaemic and haemorrhagic stroke in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med 2008;265:275-87.
20. Amarenco P, Goldstein LB, Callahan A III, Sillesen H, Hennerici MG, O'Neill BJ et al. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Atherosclerosis 2009;204:515-20.
21. Walldius G, Aastveit AH, Jungner I. Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study. J Intern Med 2006;259:259-66.
22. Juonala M, Viikari JS, Kahonen M, Solakivi T, Helenius H, Jula A et al. Childhood levels of serum apolipoproteins B and A-I predict carotid intima-media thickness and brachial endothelial function in adulthood: the cardiovascular risk in young Finns study. J Am Coll Cardiol 2008;52:293-9.
23. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007;115:459-67.
24. Charlton-Menys V, Betteridge DJ, Colhoun H, Fuller J, France M, Hitman GA et al. Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 2008;52:218-25.